Testosterone/dutasteride is a combination formulation of testosterone, an androgen, and dutasteride, a 5α-reductase inhibitor, which was under development by GlaxoSmithKline for the treatment of hypogonadism (low testosterone levels) in men in the 2000s.[1] It reached phase II clinical trials prior to the discontinuation of its development.[1]
| Combination of | |
|---|---|
| Testosterone | Androgen |
| Dutasteride | 5α-Reductase inhibitor |
| Clinical data | |
| Other names | Dutasteride/testosterone |
References
edit- ^ a b "Testosterone/dutasteride". AdisInsight. Springer Nature Switzerland AG.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |